Seven Fallen Stocks Ordered by True Worth

Several stocks now sit 30% or more below their peaks. Labels look cut in half. Yet a markdown from the top is not the same as a markdown from present business value. My job is to weigh quote against worth, not against old highs. I ordered seven names through that lens. A plain cash flow setup separates price from value. Results defy habit: steepest faller is not the finest offer.

Fund manager Paul Tudor Jones issued a stark 2027 warning. A CNBC report quotes him calling next year extremely tough for equities. His logic is blunt: buybacks plus mergers shrank share supply for years, while coming listings plus secondary sales expand it. He described the most adverse flow picture since 2002. He even plans to stay short through 2027. He added that oil could climb another $20 to $25 after autumn ballots. Such a backdrop raises danger of clutching pricey shares.

Method first, names after. I asked three questions per stock: does cash flow setup justify current quote, which growth rate would justify current quote, and does any cushion separate quote from worth? Second question is reverse math: I freeze price, solve for required growth, then weigh that rate against company history. Profits can expand while shares disappoint, because what matters is how much growth the quote already prepays.

Seventh, my weakest entry, is Apple. Shares stand up 26% since January. My cash flow setup values the business near $285, while the board shows around $341. Quote sits 16% above worth, with no cushion and a 20% premium instead. Reverse math demands 13.4% growth to defend current quote. Yet free cash flow grew 2% across five years and 7% across ten. That picture looks rich to me. Call: Wait until quote softens or cash generation jumps.

Sixth is JNJ. Stock slid 6% on report day, so I checked whether value had opened up. Sales rose and leaders lifted annual outlook. The JNJ investor page confirms $25.4B third-quarter sales plus raised guidance on October 13. But the picture splits: drug sales grew 7.7% while medtech grew 2.5%. Strong pharma carries a soft side. Valuation shows an Apple-like 20% premium. Report-day dip gave me too little protection. Call: Wait .

Fifth is Caterpillar. Shares stand up 35% this year, 53% across one year, 309% across five. Order backlog hit a $72.1B record, with $9.4B fresh orders in quarter two per a CNBC record. Sales reached $20.5B, up 24%. Demand is real, no dispute there. My question: how much improvement already sits inside the quote? After such a run, a dip means stepping back from extraordinary heights. I want firmer proof on pricing power plus leverage. Call: Wait .

Fourth is FICO. Board reads harsh: near $723, down 57% this year, with a $2,400 peak behind. Forward earnings multiple slipped below 17 against a historical 43. In theory the deepest apparent discount. Yet the reason behind the discount matters. A Reuters record shows shares fell 12% in a single April session after two housing giants accepted a rival scoring setup. Public officials then widened rivalry, and by September every lender could use the new score. Debt load also runs high. Cheap-looking is not always cheap. Call: Wait .

Third is ASML. It owns the widest moat in this set: lithography systems few others can build. A CNBC record shows the third quarter beat hopes on October 14, with fourth-quarter sales guided between 14.2B and 15.2B euros and the annual band narrowed to 44–45B euros. Some buyers signaled order interest for 2029 and even 2030. Capacity growth trails demand, and the firm hunts extra expansion paths. Business quality nears perfection. But the quote knows it, leaving thin cushion. Call: Wait .

Second is Lam Research, a force in wafer fabrication tools. A Reuters record shows September guidance near $8.1B, clearly above hopes. Industry wafer spending for 2026 moved to the lower end of the $150B band, with demand outpacing supply. NAND sales doubled in sequence. Technology plus buyer ties create worth, and returns on funds run high. But price? Earnings multiple sits near 32 against a five-year 23. A 30% slide from peak is no automatic steal, because the quote prepays stronger growth than Lam delivered for long stretches. I admire quality yet demand protection. Call: Watch with high priority.

First is Seagate. Despite retreat, shares stand up more than 170% this year. HAMR technology lifts capacity across large storage drives, while debt shrank swiftly. The Seagate investor page discloses record $3.1B free cash flow for fiscal 2026. Earnings multiple hugs its five-year average, so no visible premium like earlier names. My focal point: free cash flow is seen doubling from $3.1B toward $6B in 2027. That step must land. Strong growth beside a fair multiple earns the crown. Call: First .

One market lesson fits here. A strategist speaking on CNBC argued that rivalry cheapens tools, which then spreads AI adoption. Same shift squeezes suppliers while delighting buyers. In her view the next phase belongs not to component makers but to firms weaving AI setups into daily work. That lens matches my order: I track not who earns money, but how much hope each quote carries. Cheap hope tempts me, rich hope keeps me aside.

Closing lesson follows. Loud headline figures never erase overpayment risk. Growth resting on a narrow set adds fragility too. Judged against sales, most quotes look stretched. So my compass stays fixed: gap between quote and worth. No gap means waiting, clear gap means acting. Across these seven, the clearest gap sits at Seagate and the faintest at Apple.

My final order: 7 Apple, 6 JNJ, 5 Caterpillar, 4 FICO, 3 ASML, 2 Lam Research, 1 Seagate. Apple offers weakest entry valuation, Seagate blends risk plus return best. I follow Lam from the top row of my watchlist. Challenge my reasoning freely, and run your own arithmetic. Quotes shift, setups shift, and then the order shifts.